Loading...

REVB REVELATION BIOSCIENCES INC Product Launches 8-K Filing

RVLT

RVB

REVELATION BIOSCIENCES INC

(REVB)

2025 8-K

Show Summary

Show Summary

Equity Offerings

Financial Statements

Inflammation Results

Financial Results

Nasdaq Compliance

Corporate Presentation

Stockholder Meeting

Nasdaq Listing Update

Nasdaq Compliance

Warrant Exercise Agreement

Financial Results

Nasdaq Compliance Issues

IL-10 Increase Announcement

Warrant Exercise Agreement

Nasdaq Compliance Issue

Financial Results Announcement

Lawsuit and Judgment

Adjustment of Exercise Pric...

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

Conference Presentation

Public Offering

Reverse Stock Split

Special Meeting Approval

Financial Results Announcement

Resignation and Appointment...

Financial Results Announcement

Annual Meeting Adjournment

Financial Results and Progr...

Financial Results and Progr...

Compliance with Nasdaq List...

Public Offering

Stock Split and Increase in...

Presentation Update

External Links:

On March 17, 2025, Revelation Biosciences, Inc. announced preclinical results showing that its drug candidate Gemini reduces inflammation in human cells, and made a corporate presentation available online.

AI Assistant

REVELATION BIOSCIENCES INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.